Treats severe frostbite. Sold as Ventavis, Aurlumyn. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 14, 2026, FDA lists 3 applications for Iloprost (sold as Ventavis, Aurlumyn), first approved Dec 29, 2004, with 1 new use approved and 0 published complete response letters.
| Local Iloprost Therapy to Promote Bone Healing in High Risk FracturesNonunion Bone Fracture, Fractures Ununited · Charite University, Berlin, Germany | Phase 2 | Not yet recruiting | Nov 9, 2026 |
| Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial HypertensionPulmonary Arterial Hypertension (PAH) · University of Sao Paulo General Hospital | Phase 4 | Recruiting | Jul 20, 2026 |
| Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell DiseaseVaso-Occlusive Crises, Sickle Cell Disease · University Hospital, Rouen | Phase 3 | Not yet recruiting | Mar 27, 2026 |
| AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?Pulmonary Arterial Hypertension (PAH) · University of Sao Paulo General Hospital | Not applicable | Recruiting | Mar 9, 2026 |
| Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High AltitudeFrostbite, Altitude · Institute of Mountain Emergency Medicine | — | Not yet recruiting | Mar 4, 2026 |
| Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)Frostbite · University of Colorado, Denver | Phase 4 | Not yet recruiting | Feb 20, 2026 |
| Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial HypertensionPulmonary Arterial Hypertension (PAH) · University of Sao Paulo General Hospital | — | Not yet recruiting | Jan 21, 2026 |
| Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD)Pulmnary Hypertension, COPD · University of Sao Paulo General Hospital | Not applicable | Not yet recruiting | Dec 4, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
